We are excited to present the Brand Capital Fund’s latest insights in the consumer space with the release of our Consumer Benchmark Report, focused on The GLP-1 Economy.

Discover the Trends — This in-depth report provides valuable insights into the Health & Wellness market, covering market trends, deal activity, and early-stage fundraising benchmarks — plus a snapshot of current venture capital sentiment. Learn what’s driving decisions today and what that signals for the years ahead—download your complimentary copy today!

CONTENTS

Section 1: Beauty & Personal Care Overview + Trends

  • Part 1: Ozempic-Face to Ozempic-Everything.
    Key Insight:     1 in 8 U.S. adults have already tried GLP-1s, with awareness above 80%. Drugs like Ozempic and Wegovy are reshaping grocery baskets and fueling a market projected to hit $150B+ by 2030. Strategic buyers are racing to keep pace—M&A in nutrition, functional beverages, and supplements highlights growing appetite for wellness-aligned brands that can benefit from mega-trends like GLP-1.

  • Part 2: GLP-1–driven Adjacencies
    Key Insight:     The rise of GLP-1s is creating ripple effects across CPG—accelerating and fueling demand for protein, micronutrients, and digestive aids to address side effects like muscle loss, nutrient gaps, and diarrhea. Meanwhile, consumers searching for solutions to combat “Ozempic face” and “Ozempic breath” are sparking innovation in beauty and oral care.

Section 2: Investor Priorities in Health & Wellness for 2025

  • Part 1: Will VCs Be Investing More or Less?
     Key Insight: Investors are still bullish on health and wellness— over 90% plan to maintain or increase investment in 2025— signaling sustained confidence even in a tighter funding environment.

  • Part 2: What Matters to Investors?
     Key Insight: Repurchase rate is the #1 dealbreaker metric, with gross margin close behind—a clear sign investors are prioritizing profitability alongside growth. Top categories of interest include longevity, gut health, protein/fitness, and hydration, while adaptogens, nootropics, and intimate care are seeing waning attention.

 
 

Participating Venture Firms: